Newsroom

Dec. 12, 2018 — Sera, The Pregnancy Company(™), announced that the New York State Department of Health has issued a clinical laboratory permit for Sera to perform PreTRM® testing for pregnant women in the state of New York. The lab approval was based on the results of an on-site inspection and rigorous evaluation process. With this approval, Sera can now commercialize the PreTRM® test in New York, a very important health care market.

Nov. 27, 2018 — Sera, The Pregnancy Company(™), announces that it has completed enrollment of 5,009 women into its prospective real-time study, “A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP).”

July 1, 2018 – Sera®, The Pregnancy Company™, announces the recent launch of two new preterm birth studies using the PreTRM® test to identify high-risk mothers for intervention care.

Sera, Inc., a women’s healthcare company, announced today that Garrett K. Lam, M.D., FACOG, will be joining the company as chief medical officer on September 4, 2018. Dr. Lam will direct all clinical development activities for Sera as the company achieves its vision to be The Pregnancy Company™. He will lead a group of talented clinical operations professionals who support Sera’s collaborations with research teams across the globe.

June 19, 2018 — Sera announced today that the first patient has been enrolled in the AVERT PRETERM TRIAL. This is the second intervention study to use Sera’s PreTRM® test to identify women at high risk of early delivery that will receive proactive interventions with the goal of reducing the rate of premature delivery and improving newborn health. The principal investigator for the study is Matthew Hoffman, M.D., MPH, FACOG, Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at Christiana Care Health System in Wilmington, Delaware.

May 29, 2018 – Intermountain Healthcare announced it is launching the first study of its kind that will use Sera’s PreTRM® to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery.

Seattle, WA and Salt Lake City, February 12 – Sera, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology.

SALT LAKE CITY, November 6, 2017–Sera today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City. Dr. Critchfield’s presentation will take place at 2:30 PM E.T. on Thursday, November 9th, at the Westin Grand Central Hotel.

SALT LAKE CITY, September 5, 2017 –Sera today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Baird Global Healthcare Conference in New York City. Dr. Critchfield’s presentation will take place at 9:05 AM E.T. on Thursday, September 7th, at the InterContinental New York Barclay Hotel.

SALT LAKE CITY, June 29, 2017– Sera, Inc., a women’s healthcare company, announced today that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sera, Inc., based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.